Litcius/Paper detail

Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1

Ninaad Lasrado, Annika Rössler, Marjorie Rowe, Ai‐ris Y. Collier, Dan H. Barouch

2024Vaccine21 citationsDOIOpen Access PDF

Abstract

A new highly mutated Omicron subvariant BA.2.87.1 has recently been identified with over 30 amino acid mutations in the Spike protein compared with BA.2, BA.5, XBB.1.5, and JN.1 variants. Mutiple mutations in BA.2.87.1 are located in the N-terminal domain (NTD) rather than in the receptor binding domain (RBD) of the Spike protein. We evaluated neutralizing antibody (NAb) responses to BA.2.87.1 because of its highly mutated sequence and its unique NTD region. Our data show that NAb responses to BA.2.87.1 were lower than to BA.2 but higher than to JN.1, suggesting that BA.2.87.1 is not a further antibody escape variant compared with other currently circulating variants. Moreover, XBB.1.5 mRNA boosting increased NAb titers to all variants tested including BA.2.87.1.

Topics & Concepts

NeutralizationSpike ProteinAntibodyNeutralizing antibodyVirologyMolecular biologyTiterPeptide sequenceBiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ChemistryCoronavirus disease 2019 (COVID-19)GeneGeneticsMedicineInfectious disease (medical specialty)DiseasePathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesSARS-CoV-2 detection and testing
Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1 | Litcius